Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin.
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH , USA.
Brian T
BT
Hill
Raymond R
RR
Tubbs
Mitchell R
MR
Smith
D000079963:Brentuximab Vedotin; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D017730:Ki-1 Antigen / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000209:etiology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000378:metabolism* / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D008875:Middle Aged; D016896:Treatment Outcome
D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin